Details of the Drug Reposition

General Information of This Drug (ID: DM0XV88)

Drug Name
MK-5890   DM0XV88

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04165070) KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naive Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)